6-K
Aurora Cannabis Inc (ACB)
UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549
FORM 6-K
REPORT OFFOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2024
Commission File No. 001-38691
AURORACANNABIS INC.****(Translation of registrant's name into English)
2207 90B St. SW,
Edmonton, Alberta,
Canada T6X 1V8
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☐ Form 40-F ☒
INCORPORATION BY REFERENCE
This Form 6-K is hereby filed and incorporated by reference in the registrant’s Registration Statement on Form F-10 (File No. 333-271479).
SUBMITTED HEREWITH
| Exhibits | Description |
|---|---|
| 99.1 | Material<br> Change Report dated February 15, 2024 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AURORA CANNABIS INC.
/s/ Glen Ibbott
Glen Ibbott
Chief Financial Officer
Date: February 15, 2024
Exhibit 99.1
FORM 51-102F3
MATERIAL CHANGE REPORT
Item 1 Name and Address of Company
Aurora Cannabis Inc. (“Aurora” or the “Company”)
2207-90b Street SW
Edmonton, Alberta
T6X 1V8
Item 2 Date of Material Change
February 7, 2024
Item 3 News Release
A press release describing the material change was disseminated by Aurora on February 8, 2024 through Cision PR Newswire and can be found on SEDAR+ at www.sedarplus.ca.
Item 4 Summary of Material Change
A wholly-owned subsidiary (“Aurora Sub”) acquired the remaining approximately 90% equity interest that Aurora did not previously own of Indica Industries Pty Ltd (“MedReleafAustralia”), a leading distributor of medical cannabis products, for an enterprise value of AUD$50 million, subject to customary adjustments. Aurora paid AUD$9.45 million in cash with the balance of the purchase price satisfied by the issuance of common shares of Aurora (the “Aurora Shares”).
Item 5 Full Description of Material Change
5.1 FullDescription of Material Change
On February 7, 2024, Aurora, through Aurora Sub, purchased the remaining approximately 90% equity interest of MedReleaf Australia at a total enterprise value of AUD$50 million subject to customary adjustments (the “Transaction”). As consideration, Aurora (i) issued the selling shareholders an aggregate of 69,489,941 Aurora Shares (the “Share Consideration”); and (ii) paid the selling shareholders AUD$9.45 million in cash (the “CashConsideration” and together with the Share Consideration, the “Consideration”), subject to customary adjustments post-closing. Approximately 10% of the Consideration will be held in escrow to ensure certain obligations of the selling shareholders.
5.2 Disclosurefor Restructuring Transactions
Not applicable*.*
Item 6 Reliance on subsection 7.1(2) of NationalInstrument 51-102
Not applicable*.*
Item 7 Omitted Information
Not applicable*.*
Item 8 Executive Officer
Further information regarding the matters described in this report may be obtained from Ananth Krishnan, Vice President, Strategic Finance, who is knowledgeable about the details of the Transaction and may be contacted at [email protected].
Item 9 Date of Report
February 15, 2024.